SCHEMBL6236509

SCHEMBL6236509

[CH]1C[CH]SC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL452580 0.73
SCHEMBL43805 0.52
SCHEMBL2088 0.50
SCHEMBL342826 0.49
SCHEMBL236777 0.46
SCHEMBL8542069 0.46
SCHEMBL9866494 0.45
SCHEMBL976278 0.45
SCHEMBL2648 0.39
SCHEMBL3788025 0.39

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6465060-B1 Tetrahydrothiophene derivatives, and their use in liquid-crystalline mixtures CLARIANT INTERNATIONAL LTD. (CH) 2002-10-15 US claimed
US-20240238460-A1 IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF TELIX PHARMACEUTICALS INNOVATIONS PTY LTD (AU) 2024-07-18 US disclosed
US-12030866-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2024-07-09 US disclosed
WO-2024115733-A1 FUSED PYRROLYL-SULFONAMIDE COMPOUNDS REWIND THERAPEUTICS NV (BE) 2024-06-06 WO disclosed
EP-4347558-A1 3-PYRROLYLSULFONAMIDE COMPOUNDS AS GPR17 ANTAGONISTS ReWind Therapeutics NV (BE) 2024-04-10 EP disclosed
EP-4347541-A2 IMPROVED PROSTATE-SPECIFIC MEMBRANE ANTIGEN TARGETING RADIOPHARMACEUTICALS AND USES THEREOF Telix Pharmaceuticals (Innovations) Pty Ltd (AU) 2024-04-10 EP disclosed
WO-2024062043-A1 SUBSTITUTED PHENOTHIAZINES AS FERROPTOSIS INHIBITORS UNIVERSITEIT ANTWERPEN (BE) 2024-03-28 WO disclosed
WO-2024059119-A2 COMPOUNDS AND THEIR USE IN FILTERING ULTRAVIOLET AND/OR HIGH-ENERGY VISIBLE LIGHT SOLIOME, INC. (US) 2024-03-21 WO disclosed
US-20240059688-A1 CONOLIDINE ANALOGUES AS SELECTIVE ACKR3 MODULATORS FOR THE TREATMENT OF CANCER LUXEMBOURG INSTITUTE OF HEALTH (LIH) (LU) 2024-02-22 US disclosed
WO-2024033479-A1 (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS REMYND N.V. (BE) 2024-02-15 WO disclosed
WO-2015128344-A1 SIALIC ACID DERIVATIVES BROSSMER REINHARD (DE) 2015-09-03 WO disclosed
EP-2910561-A1 Sialic acid derivatives Brossmer, Reinhard (DE) 2015-08-26 EP disclosed
US-20150005245-A1 Sialic Acid Dimers BROSSMER REINHARD (DE) 2015-01-01 US disclosed
EP-2610263-A1 Sialic acid dimers Brossmer, Reinhard (DE) 2013-07-03 EP disclosed
EP-1539686-A1 INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE WARNER-LAMBERT COMPANY LLC (US) 2005-06-15 EP disclosed
US-20040167131-A1 Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade PFIZER INC. 2004-08-26 US disclosed
WO-2004024679-A1 INHIBITORS OF FACTOR XA AND OTHER SERINE PROTEASES INVOLVED IN THE COAGULATION CASCADE WARNER-LAMBERT COMPANY LLC (US) 2004-03-25 WO disclosed
US-6465060-B1 Tetrahydrothiophene derivatives, and their use in liquid-crystalline mixtures CLARIANT INTERNATIONAL LTD. (CH) 2002-10-15 US disclosed
US-6465060-B1 Tetrahydrothiophene derivatives, and their use in liquid-crystalline mixtures CLARIANT INTERNATIONAL LTD. (CH) 2002-10-15 US disclosed
JP-2001206884-A TETRAHYDROTHIOPHENE DERIVATIVE, AND USE OF LIQUID CRYSTAL MIXTURE CONTAINING THE SAME CLARIANT INTERNATL LTD 2001-07-31 JP disclosed